686351-24-6Relevant articles and documents
Discovery of a rapidly metabolized, long-acting β2 adrenergic receptor agonist with a short onset time incorporating a sulfone group suitable for once-daily dosing
Procopiou, Panayiotis A.,Barrett, Victoria J.,Biggadike, Keith,Butchers, Peter R.,Craven, Andrew,Ford, Alison J.,Guntrip, Stephen B.,Holmes, Duncan S.,Hughes, Sara C.,Jones, Anne E.,Looker, Brian E.,Mutch, Peter J.,Ruston, Mark,Needham, Deborah,Smith, Claire E.
supporting information, p. 159 - 170 (2014/02/14)
A series of novel, potent, and selective human β2 adrenoceptor agonists incorporating a sulfone moiety on the terminal right-hand-side phenyl ring of (R)-salmeterol is presented. Sulfone 10b had salmeterol-like potency and selectivity profile, long duration of action on guinea pig trachea, and longer than salmeterol duration of action in vivo, suitable for once-daily dosing. It had lower than salmeterol oral absorption in rat, lower bioavailability in rat and dog, and a high turnover in human hepatocytes. It was metabolized in human hepatocytes by hydroxylation, oxidation, cleavage, and conjugation; most of the metabolites would be expected to have reduced or no β2 activity. The 4-biphenylsulfonic acid was identified as a crystalline, non-hygroscopic salt of 10b, suitable for inhaled delivery. Furthermore, it was free of any genetic toxicity issues and was considered as a backup to vilanterol.
